Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Sales and Divestitures (2023 - 2024)

Historic Gains from Sales and Divestitures for Maxcyte (MXCT) over the last 2 years, with Q4 2024 value amounting to $418260.0.

  • Maxcyte's Gains from Sales and Divestitures rose 4495.23% to $418260.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $418260.0, marking a year-over-year increase of 4495.23%. This contributed to the annual value of $418260.0 for FY2024, which is 4495.23% up from last year.
  • According to the latest figures from Q4 2024, Maxcyte's Gains from Sales and Divestitures is $418260.0, which was up 4495.23% from $288550.0 recorded in Q4 2023.
  • Maxcyte's 5-year Gains from Sales and Divestitures high stood at $418260.0 for Q4 2024, and its period low was $288550.0 during Q4 2023.